Clinical Review: Safety and Efficacy Comparison between Sulfonylureas and Dipeptidyl Peptidase-4 Inhibitors as Second-Line Therapies in Type 2 Diabetes Mellitus

Author(s): Syed Wasif Gillani*, Arzu F. Moosvi

Journal Name: Current Pharmaceutical Design

Volume 26 , Issue 34 , 2020


Become EABM
Become Reviewer
Call for Editor

Abstract:

Background: According to the World Health Organization (WHO), diabetes mellitus is considered the 7th leading cause of death as of 2016, while almost half of all deaths related to high blood glucose occur before the age of 70. According to the 2019 American Diabetes Association’s (ADA) guidelines, metformin is the firstline treatment for patients with Type 2 diabetes. Additional therapy is dependent on multiple patient-specific factors, including cardiovascular risks, risk of hypoglycemia, metabolic changes, and cost. The objective of this systematic review is to analyze variables of interest in Type 2 diabetes including fasting blood glucose (FBG), post-prandial blood glucose (PPBG), hemoglobin A1c (HbA1c), microvascular complications, and cardiovascular outcomes in order to determine the shift towards the newer class of medications for type 2 diabetes.

Methods: A systematic review was conducted using ScienceDirect as the primary source of obtaining articles. This review used PRISMA for reporting and GRACE for quality assessment of ten articles. The inclusion criteria for the review consisted of patients who were on metformin therapy for a sufficient amount of time, as defined by the trial’s protocol, and who were then initiated on either a sulfonylurea (glipizide or glimepiride) or a DPP-4 inhibitor (saxagliptin or linagliptin). The articles included in this review range from 2005-2019 that are written in English only. Exclusion criteria for this systematic review were articles in which patients were not initially started on metformin therapy, were diagnosed with Type 1 diabetes mellitus, and articles that were written in languages other than English.

Results: After filtering 50 studies, 10 were selected for meeting the criteria of variables of interest. Findings suggested a significant reduction in fasting plasma glucose with 154 mg/dL + 4 mg/dL as baseline, decreasing to 132 mg/dL + 4 mg/dL with the use of glipizide & metformin combination. A similar pattern was presented with the use of saxagliptin and metformin in combination, but changes were less significant than glipizide. However, hypoglycemic events in patients who were taking glipizide with metformin versus saxagliptin with metformin; 13.4% of patients achieved HbA1c <7% without hypoglycemic events compared to 22.2% of the patients who achieved an HbA1c of <7% without hypoglycemic events.

Conclusion: Despite the higher efficacious characteristics of sulfonylureas in lowering HbA1c, due to its reported hypoglycemic effects, DPP-4 inhibitors may be considered as a clinically stable choice for second-line therapy after completing maximally tolerated doses of metformin. Sulfonylureas are considered better than DPP-4 inhibitors for treatment in patients with cardiovascular disease history and hypoglycemia.

Keywords: Sulfonylureas, glipizide, glimepiride DPP-4 inhibitors, saxagliptin, linagliptin, diabetes mellitus, fasting blood glucose, hemoglobin A1c, postprandial blood glucose, efficacy.

[1]
[2]
Dicker D. DPP-4 Inhibitors. Diabetes Care 34(2): S276.
[http://dx.doi.org/care.diabetesjournals.org/content/34/Supplement_2/S276]
[3]
Farah D, Leme GM, Eliaschewitz FG, Fonseca MCM. A safety and tolerability profile comparison between dipeptidyl peptidase-4 inhibitors and sulfonylureas in diabetic patients: A systematic review and meta-analysis. Diabetes Res Clin Pract 2019; 149: 47-63.
[http://dx.doi.org/10.1016/j.diabres.2019.01.025] [PMID: 30710655]
[4]
Feinglos M, Dailey G, Cefalu W, et al. Effect on glycemic control of the addition of 2.5 mg glipizide GITS to metformin in patients with T2DM. Diabetes Res Clin Pract 2005; 68(2): 167-75.
[http://dx.doi.org/10.1016/j.diabres.2004.09.002] [PMID: 15860246]
[5]
Gallwitz B, Rosenstock J, Rauch T, et al. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: A randomised, double-blind, non-inferiority trial. Lancet 2012; 380(9840): 475-83.
[http://dx.doi.org/10.1016/S0140-6736(12)60691-6] [PMID: 22748821]
[6]
Göke B, Gallwitz B, Eriksson JG, Hellqvist Å, Gause-Nilsson I. Saxagliptin vs. glipizide as add-on therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: long-term (52-week) extension of a 52-week randomised controlled trial. Int J Clin Pract 2013; 67(4): 307-16.
[http://dx.doi.org/10.1111/ijcp.12119] [PMID: 23638466]
[7]
González-Ortiz M, Martínez-Abundis E, Robles-Cervantes JA, Ramos-Zavala MG, Barrera-Durán C, González-Canudas J. Effect of metformin glycinate on glycated hemoglobin A1C concentration and insulin sensitivity in drug-naive adult patients with type 2 diabetes mellitus. Diabetes Technol Ther 2012; 14(12): 1140-4.
[http://dx.doi.org/10.1089/dia.2012.0097] [PMID: 22974412]
[8]
Jax T, Stirban A, Terjung A, et al. A randomised, active- and placebo-controlled, three-period crossover trial to investigate short term effects of the dipeptidyl peptidase-4 inhibitor linagliptin on macro- and microvascular endothelial function in type 2 diabetes. Cardiovasc Diabetol 2017; 16(1): 13.
[http://dx.doi.org/10.1186/s12933-016-0493-3] [PMID: 28109295]
[9]
Ott C, Raff U, Schmidt S, et al. Effects of saxagliptin on early microvascular changes in patients with type 2 diabetes. Cardiovasc Diabetol 2014; 13(1): 19.
[http://dx.doi.org/10.1186/1475-2840-13-19] [PMID: 24423149]
[10]
Pathak R, Bridgeman M B. Dipeptidyl peptidase-4 (DPP-4) inhibitors in the management of diabetes. P & T: A peer-reviewed J Formulary Management 2010; 35(9): 509-13.
[11]
Riddle MC, Blonde L, Gerstein HC, et al. Diabetes Care Editors’ Expert Forum 2018: Managing Big Data for Diabetes Research and Care. Diabetes Care 2019; 42(6): 1136-46.
[http://dx.doi.org/10.2337/dci19-0020]
[12]
Schernthaner G, Durán-Garcia S, Hanefeld M, et al. Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: A randomized, controlled study (GENERATION). Diabetes Obes Metab 2015; 17(7): 630-8.
[http://dx.doi.org/10.1111/dom.12461] [PMID: 25761977]
[13]
Sjöstrand M, Iqbal N, Lu J, Hirshberg B. Saxagliptin improves glycemic control by modulating postprandial glucagon and Cpeptide levels in Chinese patients with type 2 diabetes. Diabetes Res Clin Pract 2014; 105(2): 185-91.
[http://dx.doi.org/10.1016/j.diabres.2014.05.006] [PMID: 24947443]
[14]
Sola D, Rossi L, Schianca GP, et al. Sulfonylureas and their use in clinical practice. Arch Med Sci 2015; 11(4): 840-8.
[http://dx.doi.org/10.5114/aoms.2015.53304] [PMID: 26322096]
[15]
Rosenstock J, Kahn SE, Johansen OE, et al. CAROLINA Investigators Effect of linagliptin vs. glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: The carolina randomized clinical trial. JAMA 2019; 322(12): 1155.
[http://dx.doi.org/10.1001/jama.2019.13772] [PMID: 31536101]
[16]
Rossini AA. Why control blood glucose levels? Arch Surg 1976; 111(3): 229-33.
[http://dx.doi.org/10.1001/archsurg.1976.01360210023004] [PMID: 816331]
[17]
Weitgasser R, Lechleitner M, Luger A, Klingler A. Effects of glimepiride on HbA(1c) and body weight in Type 2 diabetes: results of a 1.5-year follow-up study. Diabetes Res Clin Pract 2003; 61(1): 13-9.
[http://dx.doi.org/10.1016/S0168-8227(02)00254-1] [PMID: 12849919]
[18]
Yang W, Pan CY, Tou C, Zhao J, Gause-Nilsson I. Efficacy and safety of saxagliptin added to metformin in Asian people with type 2 diabetes mellitus: a randomized controlled trial. Diabetes Res Clin Pract 2011; 94(2): 217-24.
[http://dx.doi.org/10.1016/j.diabres.2011.07.035] [PMID: 21871686]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 26
ISSUE: 34
Year: 2020
Published on: 12 October, 2020
Page: [4315 - 4322]
Pages: 8
DOI: 10.2174/1381612826666200408095310
Price: $65

Article Metrics

PDF: 34
HTML: 3